- Home
- TCBX vs FHTX Comparison
TCBX vs FHTX Comparison
Compare TCBX & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBX
- FHTX
- Stock Information
- Founded
- TCBX 2008
- FHTX 2015
- Country
- TCBX United States
- FHTX United States
- Employees
- TCBX N/A
- FHTX N/A
- Industry
- TCBX Banks
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- TCBX Finance
- FHTX Health Care
- Exchange
- TCBX Nasdaq
- FHTX Nasdaq
- Market Cap
- TCBX 473.0M
- FHTX 513.7M
- IPO Year
- TCBX 2021
- FHTX 2020
- Fundamental
- Price
- TCBX $34.25
- FHTX $5.14
- Analyst Decision
- TCBX Buy
- FHTX Strong Buy
- Analyst Count
- TCBX 4
- FHTX 5
- Target Price
- TCBX $25.50
- FHTX $13.80
- AVG Volume (30 Days)
- TCBX 85.4K
- FHTX 197.3K
- Earning Date
- TCBX 01-23-2025
- FHTX 11-04-2024
- Dividend Yield
- TCBX N/A
- FHTX N/A
- EPS Growth
- TCBX 38.69
- FHTX N/A
- EPS
- TCBX 2.56
- FHTX N/A
- Revenue
- TCBX $158,911,000.00
- FHTX $25,515,000.00
- Revenue This Year
- TCBX N/A
- FHTX N/A
- Revenue Next Year
- TCBX $8.54
- FHTX $11.54
- P/E Ratio
- TCBX $13.35
- FHTX N/A
- Revenue Growth
- TCBX 17.73
- FHTX N/A
- 52 Week Low
- TCBX $18.00
- FHTX $2.70
- 52 Week High
- TCBX $37.65
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- TCBX 46.12
- FHTX 27.35
- Support Level
- TCBX $36.07
- FHTX $4.69
- Resistance Level
- TCBX $37.37
- FHTX $5.70
- Average True Range (ATR)
- TCBX 1.36
- FHTX 0.61
- MACD
- TCBX -0.43
- FHTX -0.14
- Stochastic Oscillator
- TCBX 26.41
- FHTX 16.24
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company has one segment, community banking, it generates most of its revenue from interest on loans, customer service, and loan fees.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.